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Light microscopy images. In order to assess a potential increase in cell death upon 24 h GNP 
exposure (20 µg/ml), phase contrast images of the APC cultures were obtained. GNP 
formulations caused no significant impact upon APC density (Fig. S1). Interaction of citrate-
GNS was observed with both MDMs and MDDCs (Fig. S1B and S1C), although not with B 
cells (Fig. S1A). For the polymer-coated GNP, images were unable to show interactions with 
the different cell types. Thus, in view of the lack of sensitivity of light microscopy, in order to 
correctly evaluate GNP-cell association, other methods were used (DF-HSI, ICP-MS, flow 
cytometry). Addition of R848 immunostimulant did not cause any qualitative increases in cell 
death or GNP-cell interaction. LPS was used as an additional positive control to highlight 
morphological changes of activated MDM and MDDC,. 
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Figure S1. Light microscopy phase contrast images of antigen-presenting cells (APCs) exposed 
to gold nanoparticles (GNPs). B cells (A), MDMs (B) and MDDCs (C) Cells were exposed for 
24 h to GNS (20 μg/ml) with different surface functionalizations. B cells were as well exposed 
to PEG-GNR (20 μg/ml). All APCs were incubated with or without immunostimulant R848 (2 
μg/ml). MDM and MDDCs were also incubated with LPS only (100 ng/ml). Scale bars: 50  µm.  
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Table S1. ICP-MS parameters optimized for the three collision cell modes. 
Collision cell modes: [No gas] [He] [HEHe] 
Plasma mode Low matrix Low matrix Low matrix 
Plasma RF Power (W) 1550 1550 1550 
Collision gas (He) flow (mL/min) 0 4.3 10.0 
Nebulizer gas (Ar) flow (L/min) 1.0 1.0 1.0 
Auxiliary gas (Ar) flow (L/min) 0.9 0.9 0.9 
Plasma gas (Ar) flow (L/min) 15.0 15.0 15.0 
Extract 2 (V) -165 -165 -165 
Omega bias (V) -90 -90 -90 
Omega lens (V) 8.8 8.8 8.8 
Deflect (V) 13.6 0.2 -73.2 
OctP RF (V) 200 200 190 
Energy discrimination (V) 5.0 3.0 7.0 
 
 
 
Figure S2. Calibration curves for 197Au in the three collision cell modes. 
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PEG-GNR uptake by B lymphocytes. PEG-GNR were not detected in B lymphocytes by DF-
HSI (Fig. S3). A low amount of PEG-GNR associating with B cells was further confirmed and 
quantified by highly sensitive ICP-MS (as described in the main text manuscript).   
Figure S3. Dark field hyperspectral image of B lymphocytes exposed to PEG-GNR (20 µg/ml) 
for 24 h. Scale bar: 5 µm.  
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GNP-cell association via Flow Cytometry. GNPs that are internalized can be assessed by 
changes in the light scatter detected by flow cytometry. As indicated below, exposure to citrate 
GNS caused an increase in the side scatter (SSC) for B cells, but not exposure to polymer-
protected GNS (Figure S4). In contrast, in MDMs and MDDCs exposed to polymer-protected 
GNS, an increase in SSC was observed.  
Figure S4. FSC/SSC flow cytometry dot plots and histograms of antigen-presenting cells 
exposed to GNPs. All APCs were exposed for 24 h to GNS (20 μg/ml) with different surface 
functionalizations. B cells were as well exposed to PEG-GNR (20 μg/ml). 
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Figure S5. Gating strategy and B lymphocyte purity. All cells were first gated to exclude dead 
cells and cell debris followed by gating of single cells only. Next, live cells were determined by 
Zombie NIR viability dye. B cells were defined as percentage of CD20-FITC positive cells, before 
(buffy coat) and after purification. Approximately 96% B cell purity was achieved throughout the 
experiments (A). MDMs were defined as CD14-FITC positive (B) and MDDCs as CD1c-Pacific 
Blue positive cells (C). 
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MDM and MDDC activation. To compare how GNPs influence the activation potential of 
different APCs, MDMs and MDDCs were exposed to all the formulations of GNS at 20 μg/ml for 
24 h. In general, polymer-coated GNS did not impair the expression of activation markers in naïve 
as well as in R848-stimulated MDMs and MDDCs (Figure S6). It was observed that high MDM 
uptake of citrate-GNS interfered with Pacific Blue and PE-Texas Red channel, resulting in false 
decrease of  MFI for CD69 and MHC II markers (Figure S6A). No such interference was detected 
for B cells and MDDCs. There was an upregulation of CD86 in MDDCs due to PEG-GNS without 
R848. However, an endotoxin test later confirmed contamination of that specific PEG-GNS batch, 
which resulted in a false positive increase of CD86 in MDDCs (Figure S6B and Figure S9). LPS 
served as a positive control for innate immune cell activation.  
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Figure S6. MDM and MDDC activation. Surface activation markers on MDMs (CD69, CD86 and 
MHC-II) (A) and MDDCs (CD80, CD86, MHC II) (B) measured by flow cytometry after 24 h 
exposure of cells to GNS (20 μg/ml) with different surface functionalization. Cells were incubated 
with or without the immunostimulant R848 (2 μg/ml) and with LPS only (100 ng/ml). Each point 
represents one donor (n=3). Error bars: mean ± SD. Data were evaluated by two-way ANOVA, 
followed by Tukey’s multiple comparison test. 
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MDM and MDDC pro-inflammatory response. MDMs and MDDCs were tested for the 
changes in their cytokine release, following 24h exposure with different surface functionalized 
GNS (20 μg/ml). TNF-α and IL-1β release was not affected by GNS in MDM (Figure 7A) and 
TNF- and IL-6 were not altered in MDDCs (Figure S7B), whether the cells were stimulated with 
R848 immunostimulant or not. LPS served as positive control for innate immune cell activation.  
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Figure S7. MDM and MDDC pro-inflammatory response. Pro-inflammatory cytokines released 
by MDMs (TNF-α, IL1-β) (A) and MDDCs (TNF-α, IL-6) (B) after 24 h exposure of B cells to 
GNS (20 μg/ml) with different surface functionalization. Cells were incubated with or without the 
immunostimulant R848 (2 μg/ml) and with LPS only (100 ng/ml). Each point represents one donor 
(n=3). Error bars: mean ± SD. Data were evaluated by two-way ANOVA, followed by Tukey’s 
multiple comparison test. 
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Figure S8. Gold nanoparticle interference test. Gold nanoparticle interference with ELISA by 
cytokine absorption to GNP surface. Citrate-GNS, PEG-GNS and PEG-GNR were incubated in 
complete culture media with human plasma for 24 h, 37 °C, 5% CO2. H2O was added to the media 
as a negative control. Samples were then incubated with IL-6 standards for 1 h at RT, followed by 
the normal ELISA protocol. The experiment was performed once. Each point on the graphs 
represents mean of triplicates. RPMI+HP: complete culture medium consisting of RPMI with 1% 
Pen/Strep, 1% L-Glutamine, 10% human plasma. 
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Figure S9: Endotoxin test of different batches of GNPs used in the study. All batches were below 
the FDA recommended level (> 0.5 EU/ml).1 except batch #152, which was used for exposure of 
MDDCs.  
 
(1)  Food and Drug Admistration (FDA). Guidance for Industry Pyrogen and Endotoxins 
Testing 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM310098.pdf (accessed Mar 30, 2019). 
 
